

Date and time: Thursday 3 September 2015, 1000-1600

Minutes: Confirmed

Guideline Development Group Meeting 11 **Non-alcoholic fatty liver disease (NAFLD)**

Place: Boardroom, NCGC, 180 Great Portland Street, London W1W 5QZ

Present

GDG: Christopher Byrne, Professor of Endocrinology & Metabolism, University of Southampton
Chris Day, GDG Chair, Professor of Liver Medicine & Honorary Consultant Hepatologist, Newcastle University
David Fitzmaurice, Professor of Primary Care, University of Birmingham
Irene McGill, Patient/carer representative
Benjamin Mullish, ST in Hepatology & Gastroenterology, Imperial College London (Specialist Trainee Adviser)
Phil Newsome, Professor of Experimental Hepatology & Honorary Consultant Hepatologist, Birmingham University (not present for items 4 & 5)
Tanja Pardela, Paediatric Liver Modern Matron, King's College Hospital
Rachel Pryke, General Practitioner Partner, Winyates Health Centre, Redditch
Jane Putsey, Patient/carer representative (items 1-10 only)
Indra van Mourik, Consultant Paediatric Hepatologist & Clinical Lead Liver Unit, Birmingham Children's Hospital NHS Foundation Trust
Bronwen Williams, Gastroenterology and Hepatology Research Nurse, Hull Royal Infirmary
Kate Ashmore, Documents Editor/Process Assistant, NCGC (notes)
Serena Carville, Associate Director, NCGC
Lefteris Floros, Health Economist, NCGC
Jessica Glen, Senior Research Fellow, NCGC
Martin Harker, Senior Health Economist, NCGC (items 1-5 only)
Qudsia Malik, Senior Health Economist, NCGC
Amelia Unsworth, Senior Project Manager, NCGC

NICE: Jaimella Espley, Editor
Kate Moring, Costing Advisor (item 5 onwards)

Apologies: Anna Brett, Implementation Adviser, NICE
Louise Shires, Guidelines Commissioning Manager, NICE

Notes

- 1. Welcome, apologies and declarations of interest**
The Chair welcomed the group to the eleventh meeting of this GDG. The Chair advised the GDG that Kevin Moore has stepped down as a GDG member due to health reasons.

Notes

Apologies were received from AB and LS.

The Chair requested updates to the GDG members' existing DOIs. PN's existing COI with the reviews on diagnosis, severity, pharmacological interventions and HE model were noted and PN would need to leave the room for these discussions. RP declared that she is a co-author of Lancet Commission report Implementation of Lancet standing commission on liver disease in the UK due to publish in November 2015. This was classified as a specific personal non-pecuniary interest. The Chair agreed that no action was required. No other new DOIs were declared therefore no action was required.

2. **GDG10 minutes**

The minutes of the last meeting were agreed as a true and accurate record.

3. **Evidence review re-runs: Dietary modification and supplements**

The GDG reviewed the updated dietary modification and supplements review.

4. **Evidence review re-runs: Diagnosis**

PN was not present for this discussion. The GDG reviewed the updated diagnosis review.

5. **Health economic model: final results**

The GDG was given a presentation on the economic model final results.

6. **Draft algorithms: assessment and monitoring**

The GDG reviewed the draft algorithms for assessment and monitoring.

7. **Information for the public version & NICE pathway**

The GDG was given a presentation on how the recommendations will be presented in the information for the public version of the guideline and in the NICE pathway.

8. **Draft recommendations**

The GDG reviewed the draft recommendations and research recommendations.

9. **Plans for implementation**

The GDG was given a presentation on the NICE plans for implementation of the guideline.

10. **Any other business**

None.

Date, time and venue of the next meeting

GDG12: Thursday 15 October 2015, 1000-1600. *Subsequently this meeting was cancelled.*

GDG13: Monday 7 March 2016, 1000-1600, Boardroom, NCGC, 180 Great Portland Street, London W1W 5QZ